Key result
IFN-beta1b assay challenges yield ~3-5-fold lower neutralizing antibody titers than IFN-beta1a or fibroblast-derived IFN-beta.
Why the study?
Does the preparation of IFN-beta used in the assay affect the measured neutralizing antibody titers in MS patients?
Does the preparation of IFN-beta used in the assay affect the measured neutralizing antibody titers in MS patients?
The measured neutralizing antibody titers against IFN-beta in MS patients are highly dependent on the specific IFN-beta preparation used in the assay, which has implications for monitoring patient immune responses.
Answers are grounded in this paper and cite their sources.
Assay-specific NAb titers in MS warrant cautious interpretation; leaves open standardized protocols before guiding therapy.
An immune response to recombinant human protein therapeutics, including type I interferons (IFNs), has the potential to have a serious negative impact on safety and efficacy. Monitoring of patients for neutralizing antibodies (NAbs) often is advisable. In the case of IFN-beta therapy for multiple sclerosis (MS), we obtained reproducible quantitative titers of NAbs using an improved and well-characterized assay based on a 10-fold reduction of a challenge dose of IFN-beta. However, the observed titer was significantly affected by the preparation of IFN-beta used as the assay challenge. NAb titers obtained using IFN-beta1b averaged 3-5-fold lower than titers of the same sample assayed using either IFN-beta1a or human fibroblast-derived IFN-beta. This was the case whether neutralizing serum was obtained from patients on therapy with IFN-beta1a or IFN-beta1b. The reason for this apparent titer difference is not fully understood but appears to be related to protein folding or other structural properties that differentiate the IFN-beta1b both from commercial IFN-beta1a preparations and from human fibroblast-derived IFN-beta.
No takes yet. Share an insight, caveat, or question.
Files et al. (2007) studied Multiple sclerosis. IFN-beta1b assay challenge vs. IFN-beta1a or human fibroblast-derived IFN-beta was evaluated on Neutralizing antibody (NAb) titers (3-5-fold lower). Neutralizing antibody titers obtained using IFN-beta1b as the assay challenge averaged 3-5-fold lower than titers assayed using IFN-beta1a or human fibroblast-derived IFN-beta.
Synapse has enriched 10 related papers. Consider them for comparative context: